IMMUNOMODULATORY AGENTS AND PROTEASOME INHIBITORS IN THE TREATMENT OF MULTIPLE MYELOMA

被引：10

作者：

Noonan, Kimberly ^{[1
]}

Colson, Kathleen ^{[1
]}

机构：

[1] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA

来源：

SEMINARS IN ONCOLOGY NURSING | 2017年 / 33卷 / 03期

关键词：

multiple myeloma; immunomodulatory drugs; proteasome inhibitors; treatment; side effects; LENALIDOMIDE PLUS DEXAMETHASONE; STEM-CELL TRANSPLANTATION; LOW-DOSE DEXAMETHASONE; NEWLY-DIAGNOSED MYELOMA; LONG-TERM SURVIVAL; ELDERLY-PATIENTS; OPEN-LABEL; CONSENSUS STATEMENT; ANTITUMOR-ACTIVITY; ORAL MELPHALAN;

D O I：

10.1016/j.soncn.2017.05.005

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OBJECTIVE: To review the current evidence on the use of immunomodulatory agents (IMiDs) and proteasome inhibitors (PIs) in the treatment of multiple myeloma (MM). DATA SOURCES: Journal articles, research reports, state of the science papers, and clinical guidelines. CONCLUSION: There has been a tremendous increase of new agents to treat multiple myeloma in the last 15 years. The IMiDs and PIs remain essential components of many anti-myeloma regimens. IMPLICATIONS FOR NURSING PRACTICE: With these advances in the therapeutic landscape, knowledge of these drugs, side effects and nursing implications are essential to improve outcomes. Patient education is also of vital importance in achieving optimal responses to treatment.

引用

页码：279 / 291

页数：13

共 88 条

[1]

ALEXANIAN R, 1968, BLOOD, V31, P1

[2] TREATMENT FOR MULTIPLE MYELOMA - COMBINATION CHEMOTHERAPY WITH DIFFERENT MELPHALAN DOSE REGIMENS [J].

ALEXANIAN, R ;

HAUT, A ;

KHAN, AU ;

LANE, M ;

MCKELVEY, EM ;

MIGLIORE, PJ ;

STUCKEY, WJ ;

WILSON, HE .

JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1969, 208 (09) :1680-+

[3] A Phase I Single-Agent Study of Twice-Weekly Consecutive-Day Dosing of the Proteasome Inhibitor Carfilzomib in Patients with Relapsed or Refractory Multiple Myeloma or Lymphoma [J].

Alsina, Melissa ;

Trudel, Suzanne ;

Furman, Richard R. ;

Rosen, Peter J. ;

O'Connor, Owen A. ;

Comenzo, Raymond L. ;

Wong, Alvin ;

Kunkel, Lori A. ;

Molineaux, Christopher J. ;

Goy, Andre .

CLINICAL CANCER RESEARCH, 2012, 18 (17) :4830-4840

[4]

Amgen Pharmaceuticals, 2017, KYPR PACK INS

[5] Lenalidomide and thalidomide: An evolving paradigm for the management of multiple myeloma - Introduction [J].

Anderson, KC ;

Prince, HM .

SEMINARS IN HEMATOLOGY, 2005, 42 (04) :S1-S2

[6]

[Anonymous], 2015, BIOMED RES INT

[7]

[Anonymous], REVL PACK INS

[8] A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma [J].

Attal, M ;

Harousseau, JL ;

Stoppa, AM ;

Sotto, JJ ;

Fuzibet, JG ;

Rossi, JF ;

Casassus, P ;

Maisonneuve, H ;

Facon, T ;

Ifrah, N ;

Payen, C ;

Bataille, R .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (02) :91-97

[9] Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma [J].

Attal, Michel ;

Lauwers-Cances, Valerie ;

Marit, Gerald ;

Caillot, Denis ;

Moreau, Philippe ;

Facon, Thierry ;

Stoppa, Anne Marie ;

Hulin, Cyrille ;

Benboubker, Lofti ;

Garderet, Laurent ;

Decaux, Olivier ;

Leyvraz, Serge ;

Vekemans, Marie-Christiane ;

Voillat, Laurent ;

Michallet, Mauricette ;

Pegourie, Brigitte ;

Dumontet, Charles ;

Roussel, Murielle ;

Leleu, Xavier ;

Mathiot, Claire ;

Payen, Catherine ;

Avet-Loiseau, Herve ;

Harousseau, Jean-Luc .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (19) :1782-1791

[10] Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010 [J].

Brenner, Hermann ;

Gondos, Adam ;

Pulte, Dianne .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 (02) :270-275

← 1 2 3 4 5 6 7 8 9 →